VMY-1-103

CAS No. 1209002-43-6

VMY-1-103 ( VMY 1-103 )

Catalog No. M10779 CAS No. 1209002-43-6

A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VMY-1-103
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
  • Description
    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B; increases the sub G(1) fraction of apoptotic cells, induces PARP and caspase-3 cleavage and increases the levels of the death receptors DR4 and DR5, Bax and Bad.
  • Synonyms
    VMY 1-103
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1209002-43-6
  • Formula Weight
    708.27
  • Molecular Formula
    C34H42ClN9O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NCCNS(=O)(C1=C2C=CC=C(N(C)C)C2=CC=C1)=O)C3=CC=C(NC4=C5N=CN(C(C)C)C5=NC(N[C@H](C(C)C)CO)=N4)C=C3Cl
  • Chemical Name
    2-Chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ringer L, et al. Cancer Biol Ther. 2011 Nov 1;12(9):818-26.
2. Sirajuddin P, et al. Cell Cycle. 2012 Oct 15;11(20):3801-9.
3. Waye S, et al. Aging (Albany NY). 2015 Oct;7(10):854-68.
molnova catalog
related products
  • PNU-112455A

    PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively.

  • PF-562271

    PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays.

  • BS-194

    BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM.